Melatonin secretion and the incidence of type 2 diabetes

JAMA

Volumn 309, Issue 13, 2013, Pages 1388-1396

  McMullan, Ciaran J ^a,b,c   Schernhammer, Eva S ^b,c   Rimm, Eric B ^a,b,c   Hu, Frank B ^a,b,c   Forman, John P ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MELATONIN;

6 SULFATOXYMELATONIN TO CREATININE RATIO; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; FEMALE; HORMONE RELEASE; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; MAJOR CLINICAL STUDY; MELATONIN SECRETION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SLEEP QUALITY; URINALYSIS;

EID: 84875666002     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.2710     Document Type: Article

References (51)

1. Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 2010;24(5):829-841.
2. Waldhauser F, Dietzel M. Daily and annual rhythms in human melatonin secretion: role in puberty control. Ann N Y Acad Sci. 1985;453:205-214. (Pubitemid 16169260)
3. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9(1):11-24. (Pubitemid 40092915)
4. Picinato MC, Hirata AE, Cipolla-Neto J, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res. 2008;44(1):88-94. (Pubitemid 350231100)
5. Bonnefond A, Clément N, Fawcett K, et al Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC). Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet. 2012;44(3):297-301.
6. Prunet-Marcassus B, Desbazeille M, Bros A, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology. 2003;144(12):5347-5352. (Pubitemid 37476063)
7. Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine. 2003;21(2):163-167. (Pubitemid 36936358)
8. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150(12):5311-5317.
9. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89-94.
10. Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77-81.
11. Soranzo N, Sanna S, Wheeler E, et al WTCCC. Common variants at 10 genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways [published correction appears in Diabetes. 2011;60(3):1050-1051]. Diabetes. 2010;59(12):3229-3239.
12. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313(17):1044-1049. (Pubitemid 16243331)
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(suppl 1):S64-S71.
14. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991;338(8770):774-778.
15. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab. 1981;53(3):645-650. (Pubitemid 12005815)
16. Baskett JJ, Cockrem JF, Antunovich TA. Sulpha-toxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res. 1998;24(1):58-61. (Pubitemid 28161022)
17. Griefahn B, Remer T, Blaszkewicz M, Bröde P. Long-term stability of 6-hydroxymelatonin sulfate in 24-h urine samples stored at -20 degrees C. Endocrine. 2001;15(2):199-202. (Pubitemid 32977330)
18. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 2004;13(6):936-943. (Pubitemid 38756703)
19. Bertone ER, Willett WC, Rosner BA, et al Nurses' Health Study. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst. 2001;93(12):942-948. (Pubitemid 32624652)
20. Hu FB, Rimm E, Smith-Warner SA, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr. 1999;69(2):243-249.
21. de Koning L, Chiuve SE, Fung TT, Willett WC, Rimm EB, Hu FB. Diet-quality scores and the risk of type 2 diabetes in men. Diabetes Care. 2011;34(5):1150-1156.
22. Oh K, Hu FB, Cho E, et al. Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. Am J Epidemiol. 2005;161(2):161-169. (Pubitemid 40096791)
23. McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24(3):460-464. (Pubitemid 32198413)
24. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205-213. (Pubitemid 20126858)
25. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993;22(6):1189-1192. (Pubitemid 24025700)
26. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452-1459.
27. Ayas NT, White DP, Al-Delaimy WK, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care. 2003;26(2):380-384. (Pubitemid 36929059)
28. Shimakawa T, Herrera-Acena MG, Colditz GA, et al. Comparison of diets of diabetic and nondiabetic women. Diabetes Care. 1993;16(10):1356-1362.
29. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006;29(7):1585-1590. (Pubitemid 44127585)
30. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA. 2003;289(14):1785-1791. (Pubitemid 37430247)
31. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23(10):1777-1781. (Pubitemid 41830411)
32. Cuesta S, Kireev R, García C, Rancan L, Vara E, Tresguerres JA. Melatonin can improve insulin resistance and aging-induced pancreas alterations in senescence-accelerated prone male mice (SAMP8). Age (Dordr). 2012.
33. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol. 2002;191(2):157-166. (Pubitemid 34626621)
34. Ramracheya RD, Muller DS, Squires PE, et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res. 2008;44(3):273-279. (Pubitemid 351392941)
35. Peschke E, Frese T, Chankiewitz E, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40(2):135-143.
36. Hikichi T, Tateda N, Miura T. Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:655-660.
37. Robeva R, Kirilov G, Tomova A, Kumanov P. Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. Andrologia. 2006;38(6):216-220. (Pubitemid 44690785)
38. Robeva R, Kirilov G, Tomova A, Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. J Pineal Res. 2008;44(1):52-56. (Pubitemid 350231109)
39. Kwak SH, Kim SH, Cho YM, et al. A genome-wide association study of gestational diabetes mellitus in Korean women. Diabetes. 2012;61(2):531-541.
40. Ohshige T, Iwata M, Omori S, et al. Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One. 2011;6(10):e26911.
41. Ramos E, Chen G, Shriner D, et al. Replication of genome-wide association studies (GWAS) loci for fasting plasma glucose in African-Americans. Diabetologia. 2011;54(4):783-788.
42. Dupuis J, Langenberg C, Prokopenko I, et al DIAGRAM Consortium; GIANT Consortium; Global BP-gen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-116.
43. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):74-79.
44. Schernhammer ES, Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004;90(5):941-943. (Pubitemid 38495808)
45. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006;29(3):657-661. (Pubitemid 44115369)
46. Al-Delaimy WK, Manson JE, Willett WC, Stampfer MJ, Hu FB. Snoring as a risk factor for type II diabetes mellitus: a prospective study. Am J Epidemiol. 2002;155(5):387-393. (Pubitemid 34174148)
47. Buxton OM, Cain SW, O'Connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med. 2012;4(129):ra43.
48. Diethelm K, Libuda L, Bolzenius K, Griefahn B, Buyken AE, Remer T. Longitudinal associations between endogenous melatonin production and reported sleep duration from childhood to early adulthood. Horm Res Paediatr. 2010;74(6):390-398.
49. Hernández C, Abreu J, Abreu P, Castro A, Jiménez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J. 2007;30(3):496-500. (Pubitemid 351182073)
50. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res. 1998;24(4):230-238. (Pubitemid 28206444)
51. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113(25):2914-2918. (Pubitemid 44297232)